Record EBITDA, But Q1 Marks the Peak; Raised Guidance Banks on Structural Gains, Not Transient Tailwinds
Galaxy's ₹35,458 EBITDA per metric ton in Q1 is acknowledged exceptional, driven by West Asia pricing windfall and inventory stocking. Management's raised FY27 guidance (₹24,000–25,000/MT) rests on structural improvements—specialty mix, US tariff recovery, India reformulation—but requires H2 to normalize to ₹21,000–22,000/MT without slipping further.
₹165.9 Cr
+108.7% YoY
₹35,458
Management: elevated
₹24,000–25,000
Raised from ₹19,000–21,000
₹21,000–22,000/MT
Per management
Galaxy Surfactants' first quarter profits nearly doubled on paper, but the headline masks a story of transient tailwinds masking a more measured structural improvement. Net profit hit ₹165.9 crore, up 108.7% year-on-year, and EBITDA surged to ₹252.5 crore—an 86.8% jump. But the company's own guidance tells you exactly where the quarter stands: Q1's ₹35,458 EBITDA per metric ton was elevated, and full-year normalization to ₹21,000–22,000/MT in H2 is explicitly priced into the raised FY27 guidance of ₹24,000–25,000/MT.
Where Q1's Exceptional Per-Ton EBITDA Came From
Of the 77% increase in EBITDA per metric ton year-on-year, only a fraction flows from core business strength. The rest rides on three transient props: West Asia supply disruption (seven weeks of port congestion in April–May at Jebel Ali, Geisum, and Jeddah pushed freight costs up 100% and raw materials into stocking mode), customer inventory building ahead of supply fear and festive season demand prep, and product mix shift within the performance portfolio (70% active products vs. 100% prior, commanding higher prices). Combine these with reformulation tailwinds—oleochemicals now favored over petrochemical derivatives—and the ASP jumped 34% while volume grew just 5%. Volume guidance came in at 5%, one percentage point below the 6–8% range, though management characterized it as close to reiterate full-year expectations.
Claims vs. Reality: What Holds Up
Record quarterly EBITDA ₹252.5 Cr, up 87% YoY
5% consolidated volume growth (India 11%, RoW 6%, AMET −4%)
EBITDA per MT ₹35,458 is elevated; normalized to ₹21–22k in H2
Raised FY27 EBITDA/MT guidance to ₹24–25k from prior ₹19–21k
Freight costs doubled; passed to customers on CIF pricing basis
All major claims trace to the delivered numbers and hold up under scrutiny. The profit surge, volume splits, and EBITDA arithmetic all check out. The critical difference: management's honesty about Q1 being an outlier. Rather than let investors extrapolate a new baseline, they explicitly pegged Q2–Q4 guidance at ₹21–22k/MT, which means the ₹24–25k full-year guidance requires structural gains (specialty mix uplift, US tariff clarity restoring TRI-K premium specialty volumes, India reformulation tailwinds) to offset H2 normalization. That's credible discipline on their part—and a warning for investors who read the headline number as repeatable.
What Changed on This Call
The guidance move is the headline: EBITDA per metric ton raised by ₹5,000 (a 26% midpoint increase). But the substantive changes run deeper. US tariff risk is off the table—clarity on trade policy is now a tailwind. TRI-K premium specialties are moving, and customer project approvals have resumed since tariff normalization in February. India's reformulation dynamics shifted decisively toward oleochemical-based products, where Galaxy has scale; volumes hit 11% growth as proof. On the flip side, AMET market churn crystallized: one major customer backward-integrated in Egypt, a structural loss. Management is diversifying geographically within AMET to offset, but the headwind is acknowledged and real. Finally, volume guidance was maintained despite the 1-percentage-point miss (5% actual vs. 6–8% range), suggesting confidence in H2 acceleration in India and AMET recovery now that supply constraints are easing.
The Bull Case
Galaxy has structural tailwinds that justify the raised guidance if executed. Specialty ingredients, the stated growth engine toward a 60–70% mix by 2030, are accelerating: SimpliX (innovative platform for personal care), Biosurf (enzyme surfactant), and Everbond (super-specialty super-specialty from TRI-K) all launched with customer traction. The Mexico EPC (engineering, procurement, construction) project is on track for FY27 commercialization, adding a new revenue stream. US demand is strengthening post-tariff. India's oleochemical favorability is here now, not theoretical. And the company has pricing power: when customers understand the cost rationale (freight doubling, commodity inflation, rupee depreciation), they accept increases. Margins are expanding—OPM 14%, NPM 9.3%—and the capital-light model means high operational leverage if volume follows. None of this depends on West Asia staying disrupted or inventory staying bloated.
The Bear Case
But three risks loom large enough to keep this from being a step-change story. West Asia geopolitical risk is live: Q1's seven-week port disruption proved how quickly supply chains fracture. If Jebel Ali or Jeddah choke again, freight will spike and margins compress unless customers absorb hikes—unlikely if demand softens. Monsoon deficit in India is a wildcard management explicitly flagged. Rural demand is material to Galaxy's India momentum; poor rains could derail the 11% growth trajectory. AMET's structural churn is a permanent drag: the customer backward-integration is a loss, and while demand is resilient, the geography remains weaker than management's optimism suggests. Freight cost normalization is a tail risk: if the 100% spike normalizes and customers resist further hikes, EBITDA per ton compresses faster than guided. And reformulation risk cuts both ways: if crude crashes and petrochemical prices crater while alcohol stays elevated, customers revert to petrochemical, and specialty mix uplift reverses.
The Street's View
The market bought the story on day 1 with a +20% pop, and the move held through day 3 (+16.43% from the pre-result close of ₹2,090.4). That's a market verdict that the raise is credible. However, the stock has since retreated to ₹2,318.2 and sits −12.45% from its all-time high of ₹2,648. While Galaxy is above its 20-day, 50-day, and 200-day moving averages (₹2,100.51, ₹2,000.86, ₹1,929.82 respectively), it is not overbought by technicals (RSI 68.6 is neutral). Institutional flows are measured: FII ownership ticked down 17 basis points quarter-on-quarter to 3.82%, while DII added 42 basis points to 13.52%. Promoter ownership remains steady at 70.90%. The slight FII trim post-result suggests that even as the fundamental story brightened, some institutions are taking profit—a signal that the valuation is not seen as egregiously cheap despite the raised guidance.
Guidance raised 26% midpoint on structural gains, not transient tailwinds
Specialty ingredients momentum genuine; SimpliX, Biosurf, Everbond launched with traction
India 11% volume growth; oleochemical tailwinds are here now
US tariff risk eliminated; TRI-K premium specialties recovering
Management transparent on Q1 being elevated; explicitly guided H2 normalization
Q1 EBITDA/MT exceptional at ₹35,458; H2 guided ₹21–22k is a sharp drop-off
Volume guidance 6–8% missed at 5%; need 7%+ in H2 to hit target
AMET structural headwind crystallized; major customer backward-integration is permanent
West Asia geopolitical risk live; 7-week port disruption in Q1 is template for downside
Monsoon deficit could derail India rural demand; flagged as key Q2 unknown
Freight cost normalization is tail risk; margin compression if not fully passed to customers
FII trimming slightly post-result (−17 bp); valuation not seen as cheap despite raise
West Asia geopolitical escalation
HighQ1 saw seven weeks of port congestion (Jebel Ali, Geisum, Jeddah). Freight doubled. If recurs, supply chains fracture, margins compress unless customers absorb hikes—unlikely if demand softens.
Monsoon deficit outcome (clarity by end-Q2)
HighRural demand is material to India's 11% growth. Poor rains derail Q2–Q4 volumes below the 7%+ needed to hit 6–8% guidance. Management flagged this as key Q2 unknown.
AMET customer churn and market structure
Medium-HighMajor customer backward-integrated in Egypt; permanent loss. Volumes down 4% YoY despite strong sequential recovery. Diversification underway but headwind is real and crystallized.
Freight cost normalization
MediumFreight doubled in Q1 (embedded in CIF). If normalizes and customers resist hikes, EBITDA per ton compresses faster than guided. Tail risk but material to margin guidance.
Reformulation reversal (petrochemical vs. oleochemical)
MediumCurrently oleochemical favored. If crude crashes and alcohol stays elevated, customers revert to petrochemical and specialty mix uplift reverses. Dual-feedstock capability mitigates but not immune.
1 · Monsoon outcome (clarity by end-Q2)
The single biggest Q2 risk to fundamentals. Poor rains derail India rural demand and could force volume guidance down.
2 · H2 EBITDA per MT realization (₹21–22k guidance)
Does H2 normalize as guided, or undershoot due to West Asia recurrence, freight normalization, or inventory depletion? This credibility test of the raised guidance.
3 · New product traction (SimpliX follow-ups, inorganic targets)
M&A flagged as part of Beauty & Wellness strategy but announcement deferred. If products or deals accelerate specialty mix, it validates structural uplift. If stalled, growth is flatter.
4 · Mexico EPC commercialization (FY27 completion)
New revenue stream not materially impacting Q1. Successful launch adds confidence to raised guidance; delay would crimp full-year upside.
5 · Fatty alcohol price trajectory (forecast ₹2,600–2,800/ton)
Management guides stable feedstock ahead. If crude or palm oil spikes (El Niño risk, biodiesel mandate variability), input volatility returns and margin guidance is at risk.
Galaxy Surfactants delivered what the market wanted—record profits, raised guidance, structural tailwinds—but with one critical caveat baked in: Q1 is the peak, and H2 normalization is priced into the ₹24–25k guidance. That's not a red flag; it's honesty. The business has genuine momentum: specialty ingredients are launching with traction, US tariff headwind is gone, and India's reformulation dynamics are favorable. But the raised guidance does not represent a step-change in earning power; it represents management's confidence that structural gains offset a normalizing H2. Whether that holds depends on monsoon, geopolitics, and customer appetite for price hikes as freight normalizes.
The number to track from here is H2 EBITDA per metric ton. If Galaxy delivers ₹21–22k as guided, the fundamental case is intact and the stock deserves multiple recognition for specialty mix uplift. If H2 undershoots (say, ₹19–20k due to monsoon weakness, West Asia flare, or freight normalization headwinds), the raised guidance loses credibility and the pop reverses. The next two quarters will tell. Until then, this is a show-me story at ₹2,318.2—good business, good strategy, but the structural thesis is not yet proven.
Record EBITDA, but Q1 peak transient; H2 normalization expected
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Buy
confidence 7/10
Grade B+
Delivered Q1 volume growth of 5% vs prior 6-8% guidance (1pp miss, close). Raised EBITDA per MT guidance this call; FY26 full-year ₹19k baseline shows ₹24-25k is meaningful if realized.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Record EBITDA (+87% YoY) and PAT near-doubled on strong pricing/mix despite modest 5% volume growth. Raised EBITDA per MT guidance 24-25% above prior range (₹24-25k vs ₹19-21k). Structural tailwinds intact: specialty ingredients recovering, US tariff normalization, India reformutation favorable. KEY RISK: Q1's ₹35.5k EBITDA/MT is acknowledged elevated (West Asia crisis pricing gains, inventory stocking); H2 expected at ₹21-22k normalized. AMET market structural headwinds and monsoon deficit risk cap upside.
₹1781.9 Cr
Revenue · +39.4% YoY₹165.9 Cr
Reported PAT · +108.7% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Record quarterly EBITDA ₹252.5 Cr, nearly doubling profitability
METEBITDA +86.8% YoY (₹135.1→252.5 Cr), PAT +108.7% YoY. Revenue +39.4% on 5% volume growth.
5% consolidated volume growth with India 11%, RoW 6%, AMET -4%
METStated figures match management narrative. AMET offset by India/RoW strength.
EBITDA per MT ₹35,458, up from ₹20,009 prior year
METRepresents 77% increase. Driven by reformulation recovery, specialty mix, West Asia pricing gains, inventory stocking. Management explicitly states this is elevated.
Expect normalized EBITDA per MT of ₹21,000-22,000 for Q2-Q4
CorroboratedGuidance range ₹24,000-25,000 for full FY27 implies Q1 weighted heavily. Q1 was ₹35.5k; average of ₹21k (next 3 quarters) = (35.5 + 3×21)/4 = ₹24.6k midpoint ✓
Freight costs more than doubled; reflected in pricing
METNot quantified in results, but acknowledged in Q&A as cost inflation passed to customers via CIF pricing.
Earnings quality
What changed since the last call
EBITDA per MT guidance raised
UpgradePrior ₹19,000-21,000 → New ₹24,000-25,000 for FY27. Midpoint +28%. Reflects structural gains in specialty mix and US recovery.
US tariff risk normalized
UpgradeTariff clarity removed prior headwind. Everbond new product momentum, customer project approvals flowing. TRI-K premium specialties strong.
India reformulation balance shifted
UpgradeOleochemical now favored vs petrochemical due to cost dynamics. Volumes recovered to 11% growth. Risk remains if crude drops materially.
AMET market churn crystallized
DowngradeCustomer backward integration permanent loss in Egypt. Mitigated by geographic diversification, but structural headwind acknowledged. Demand resilient; supply-led recovery in progress.
Volume guidance maintained despite miss
NeutralQ1 achieved 5% (below 6-8% range), but management confident on India/AMET momentum for H2 ramp. Implies 7%+ needed in Q2-Q4.
The Q&A
Analysts pressed hard on Q1 EBITDA sustainability (Sanjesh, Jignesh). Management held firm on raised guidance but explicitly acknowledged ₹35.5k is elevated and normalized to ₹21-22k. Refused to quantify transient inventory/pricing gains. Concerns on H2 demand (monsoon risk, H2 demand seasonality) and AMET recovery were not definitively resolved. Overall: confident tone but caveated; analysts seemed satisfied.
Q1 EBITDA sustainability — Sanjesh, ICICI Securities
PartialReformulation recovery gave volumes back + operating leverage. Specialty mix improving. US tariff recovery. Some commercial opportunities selective. H2 guidance ₹21-22k/MT factors structural gains.
US market outlook — Sanjesh, ICICI Securities
AnsweredTRI-K premium specialties strong. Everbond new product showing significant momentum, meaningful revenue contribution. Customer approvals falling in place Feb onwards as tariffs came down. Expect continuation.
Reformulation risk reversal — Sanjesh, ICICI Securities
AnsweredBalance currently favorable for oleo. If petrochemical prices drop significantly + alcohol prices stay elevated, risk exists. But we have petrochemical derivative capacity ready; all approvals in place. Flexibility built-in.
Indonesia biodiesel mandate impact — Rohit Nagraj, 360 ONE Capital
AnsweredPalm oil prices already factored mandate in. Forecast stable at ₹2,600-2,800 per ton. No significant jumps or corrections expected. Stability aids business management.
Inventory stocking — Rohit Nagraj, 360 ONE Capital
PartialGST rationalization flushed prior stocks to Nov. Momentum restarted Jan-Feb. West Asia crisis + festive season demand prep drove some extra buying. Momentum still healthy; customers preparing for festive demand.
Volume guidance confidence — Rohit Nagraj, 360 ONE Capital
AnsweredConfident. AMET demand not an issue; supply constraints resolved now. India showing good momentum. No black swan seen. Only risk if demand impacted by external shock.
Gross margin outlook & rupee — Arun Prasath, Avendus Spark
PartialWould like it, but need to wait. Don't want to overpromise/under-deliver. Re-evaluating, but would wait at least one quarter before raising guidance further.
Pricing pressure on rupee terms — Arun Prasath, Avendus Spark
AnsweredNo pressure. Transparency with customers on pricing rationale. When they understand reasons (cost pass-through, rupee, commodities), they accept. Customers trust our honest engagement.
H2 volume growth outlook — Arun Prasath, Avendus Spark
PartialGuidance factors all this. Q2 momentum intact per customer commentary. Monsoon deficit answer by end-Q2. If not an issue, H2 very different and better. Customers indicating Q2 momentum clear.
Strategy 2030 execution — Arun Prasath, Avendus Spark
AnsweredIntroduced Beauty & Wellness segment, Leaveon via Emollient/Esters. Launched SimpliX, Biosurf, Everbond. Projects in pipeline. Inorganic component planned but no announcement yet; work happening. Capex ₹150 Cr annually across initiatives.
Pricing gain breakdown — Jignesh Kamani, Nippon Mutual Fund
PartialFreight doubled (CIF embedded). Mix changed within performance portfolio (70% vs 100% active products). Better prepared when headwinds became tailwinds. Achieved ₹35,000/MT; H2 normalized to ₹21-22k /MT.
Specialty mix decline as % — Aditya Khetan, SMIFS
PartialWithout transients, would still be ~₹21,000/MT. Denominator increased (performance grew more). Specialty absolute terms showed very good growth. Signals structurally specialty momentum sustaining.
International markets structural demand — Aditya Khetan, SMIFS
AnsweredEurope: Projects in pipeline not maturing due to customer caution; gotten better now. U.S.: Demand upbeat, economy growing, inflation easing per Fed. No structural demand worry U.S.; some approval time lag for new products but improving.
Fatty alcohol price trajectory — Umang Shah, Banyan Tree Advisors
PartialTechnically should decline, but El Nino next year will impact production. Indonesia 40-50% biodiesel mandate adds variability. Multiple moving parts. Quarter-on-quarter management best approach.
AMET capex plans — Umang Shah, Banyan Tree Advisors
AnsweredCapex done. Only debottlenecking investments going forward. No acquisitions planned in AMET. Market not structurally worsening; diversifying to other markets within AMET region.
EPC project revenue — Tanvi Warekar, Anand Rathi
DodgedDue to customer confidentiality, can't disclose numbers. Not materially impacting overall results. Will be completed by end-FY27. Separate business segment.
Contract pricing mechanism — Rohit, Sunidhi Securities
AnsweredContractual business has clear latent cost-increase/decrease pass-through methodology. Spot prices revised as needed. Transparency with customers ensures fair observation of cost changes.
Inorganic expansion timeline — Rohit, Sunidhi Securities
PartialProgressing well on evaluation and mandate setting. Need right fit, accretive to profitability, aligned with strategy. Hope to announce in coming quarters. Won't do anything just for FOMO.
Performance vs specialty strategy — Bhavesh, DV Investment Advisors
AnsweredNo transition strategy. Growing both legs equally. More products launching next quarter. New products contribute >5% revenue/margins by 2030. First-to-market positioning gives us competitive edge; customers take time on approvals.
Industry tailwind — Ishika Bajaj, Kredent Family Office
AnsweredIndustry demand resilient despite inflation. We have largest portfolio in India and larger scale/customer base than peers. Differentiated business model underscores robustness.
Guidance
FY27 volume growth 6% to 8% (maintained from prior)
HighQ1 achieved 5%; expect H2 acceleration. India momentum robust; AMET recovery underway. Contingent on no new geopolitical black swan.
EBITDA per MT ₹24,000 to ₹25,000 for FY27 (raised from ₹19,000-21,000)
MediumQ1 achieved ₹35,458 (elevated). Q2-Q4 expected ₹21,000-22,000 normalized. Average = ₹24-25k implies structural gains offset normalizations.
Annual capex ₹150 Crores (maintained)
HighAllocated to capacity for specialty ingredients growth, Beauty/Wellness portfolio, Mexico EPC completion, debottlenecking in AMET.
Risks the call surfaced
Geopolitical supply chain
HighQ1 saw 7 weeks of AMET (Egypt) raw material stocking due to port congestion (Jebel Ali, Geisum, Jeddah). Ports still congested; transit times elevated; freight rates doubled.
Commodity price volatility
MediumFatty alcohol prices moved USD 2,800→3,300→2,500/MT within Q1 (18% intra-quarter swing). Indonesia 40-50% biodiesel mandate, El Niño next year add variability.
AMET market structure
HighOne major customer backward integrated in Egypt local market; permanent loss of volumes. AMET volumes down 4% YoY despite strong recovery narrative.
Reformulation risk
MediumCurrently oleochemical favorable (high) vs petrochemical (lower). If crude drops 30%+ and alcohol prices stay elevated, customers revert to petrochemical, impacting specialty ingredients.
Demand seasonality & macro
MediumManagement flagged monsoon deficit impact as key unknown for H2 earnings. If rural demand impacted, H2 volume growth could fall short of 6-8% target.
Management
Score 7/10. Clear on strategy (Strategy 2030, dual-leg growth). Transparent on challenges (West Asia, AMET, reformulation risk, monsoon uncertainty). Detailed regional breakdowns. But refused to quantify transient inventory/pricing gains, suggesting some opacity on earnings quality. Strong track record: navigated two years of disruption (tariffs, reformulations, supply chains). This quarter delivered exceptional results. India 11% growth and AMET recovery show operational agility. Prior guidance on tariff normalization proven prescient.
1 · Q2 FY27
Monsoon outcome; rural demand clarity by end of Q2
2 · Q2-Q4 FY27
Fatty alcohol price stability ₹2,600-2,800; supply recovery easing freight
3 · Next 2-3 quarters
New product launches (SimpliX follow-ups); Beauty/Wellness M&A announcement hoped
AMET market structural headwinds and monsoon deficit risk cap upside.
Margin Story Meets Volume Recovery — Expect Guidance Steady
Galaxy Surfactants reports Q1 FY27 before the market Wednesday. The read: raw-material headwinds and wage inflation have clipped margins; the watch is whether specialty-care growth and early pricing action begin to lift. Street holds consensus buy; FY27 EBITDA/MT guidance of ₹19–₹20k sets the bar.
What to Expect
~₹1,300–₹1,350 Cr
Tracking Q4 FY26 (₹1,315 Cr); seasonal Q1 typically flat to slightly softer; volume trends mixed
~9–10%
Q4 was 9.25%; input costs and wage inflation remain headwinds; pricing action and mix-shift to specialty the lever
~₹65–₹75 Cr
Q4 FY26 was ₹76 Cr; assumes stable operating leverage but watch near-term cost absorption
Performance -HS%, Specialty +HS%
Q4 saw performance surfactants soften; specialty care outperformance to continue; North America recovery potential
Strong quarter: Revenue ₹1,350+ Cr with EBITDA margin holding 10%+ — signals pricing power, cost control, and specialty momentum offsetting commodity headwinds. Weak quarter: Revenue below ₹1,300 Cr or margin slipping below 9% — would suggest pricing actions stalled, input costs re-inflated, or specialty deceleration. Focus: EBITDA per MT vs. ₹20k guidance and gross margin trajectory.
On Track?
Galaxy is tracking cautiously toward FY27 guidance. The ₹19–₹20k EBITDA per tonne target is ambitious given Q4's 276 bps margin erosion (operating margin fell from 12.01% in Sept 2024 to 9.25% in Mar 2026). Management cited raw-material volatility, supply-chain disruption, and wage inflation; the near-term recovery lever is pricing action and specialty-mix shift. If Q1 sustains ₹20k+ per MT, confidence rebuilds. If it falls below ₹19.5k, the full-year target is at risk, and Street targets may reset downward.
What the Street Says
Since Last Quarter
May 14
Q4 FY26 & FY26 audited results announced
Revenue ₹1,315 Cr, PAT ₹76 Cr; EBITDA margin 9.25% (compressed). Final dividend ₹22/share approved.
May 15
Rajib Bhattacharjee (VP, Value Acceleration) resigns
Routine management move; no material operational flag.
Jul 9
Record date set for FY26 dividend
July 31 record date confirmed; dividend paid as scheduled.
Jul 17
FY26 Annual Report filed; AGM notice issued (Aug 12)
BRSR (ESG report) filed in compliance. 40th AGM on Aug 12; no governance red flags.
Aug 6
Board meeting intimation for Aug 13 (Q1 FY27)
Q1 results to be approved on Aug 13 (today in report context). Standard agenda.
Summary of filings: No material adverse corporate actions or insider pledges reported. Promoter holding stable at ~70.9%. Dividend payment routine. Management change (VP exit) is routine and does not signal operational stress. The trading window closure in late June is standard pre-result protocol.
3 Things to Watch on Result Day
1 · EBITDA per MT — is it ≥₹19,500?
Management's FY27 guidance of ₹19–₹20k per MT is the north star. Q4 was ₹20,113. A Q1 print below ₹19,500 signals margin recovery has stalled and raises full-year delivery risk. Watch management commentary on pricing realization and mix.
2 · Specialty care revenue share — is it >37% of total?
Specialty is the margin-lift story. Q4 specialty revenue was ~₹4,976 Cr of ~₹13,150 Cr total (37.8%). If Q1 specialty share stays above 37–38%, the mix-shift narrative holds. A slip back to 35% would disappoint.
3 · Management guidance on input costs & North America recovery
Raw-material inflation and wage cost trends are the key drag. Listen for (a) forward guidance on pricing actions, (b) update on North American volume recovery (cited as a FY27 tailwind), and (c) any reset to full-year EBITDA per MT target or FY27 PAT outlook.
Galaxy Surfactants faces a classic margin-recovery inflection quarter. The tailwinds (specialty growth, pricing actions, North America rebound) are credible; the headwinds (input costs, wage inflation) are real and persistent. For the Street's ₹2,383 consensus target to hold, Q1 must signal that pricing traction and mix improvement are outpacing cost growth — and that ₹19–₹20k EBITDA per MT is achievable across FY27. If margins slip further, target downgrades will follow. Watch the EBITDA/MT print and guidance tone closely.
Galaxy Surfactants Q1 FY27: Consol PAT doubles YoY to ₹165.9 Cr, OPM jumps to ~14%
PAT +108.73% YoY · revenue +39.44% · margins expanding · beat vs street
₹1,781.9 Cr
+39.44% YoY
₹165.92 Cr
+108.73% YoY
9.29%
+3.1pp YoY
₹46.8
Galaxy Surfactants' consolidated PAT (primary basis) came in at ₹165.9 Cr for Q1 FY27, up 108.7% YoY from ₹79.5 Cr and up 165.8% QoQ from ₹62.4 Cr, on revenue of ₹1,781.9 Cr (+39.4% YoY, +35.5% QoQ). Standalone PAT was ₹105.9 Cr (+152% YoY on revenue of ₹1,265.5 Cr, +44.8% YoY) — standalone grew profit faster in percentage terms than consolidated, a divergence of more than 3 points that reflects the outsized consolidated contribution described below rather than any weakness at the parent. Net margin expanded to 9.3% from 6.2% YoY, and operating margin (EBITDA/revenue ex-other income) jumped to ~14.0% from 9.7% a year ago and 9.25% last quarter — independently corroborated by market data showing EBITDA margin near 13.97% for the quarter.
Q1 FY-2027 vs prior quarters
The margin bridge is broad-based rather than a single line item: materials cost stayed roughly flat at ~72.5% of revenue (versus 72.5% YoY, 73.6% QoQ), but employee costs fell to 5.6% of revenue from 6.5% YoY, and other expenses eased to 9.7% from 10.0% YoY, pulling total expenses down to 88.6% of revenue from 93.1% YoY — consistent with operating leverage on higher volumes/pricing. A material part of the consolidated upside, however, sits in one subsidiary the principal auditor did not itself review: it contributed ₹430.1 Cr of revenue and ₹47.8 Cr of PAT (about 24% and 29% of consolidated totals respectively), per the review report — a scale that makes this quarter's consolidated jump partly dependent on that entity's numbers holding up once fully audited.
The stock went into the print at ₹2,090.4, up 6.3% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 2 consecutive quarters; revenue is at a 6-quarter high.
What the summary numbers don't show
No exceptional items this quarter (FY26 full year carried a ₹11.9 Cr exceptional charge)
Consolidated basic EPS ₹46.80 vs ₹17.60 QoQ and ₹22.42 YoY
Management provided a Q1 FY27 volume growth guidance of 6% to 8% and EBITDA per metric ton in the higher end of INR19,000 to INR21,000, contingent on the current scenario persisting. For the full fiscal year, they anticipate sequential improvement, with the India business expected to maintain its robust growth momentum
— This quarter: beat
Our pre-result preview had pencilled in consolidated revenue of ₹1,300–1,350 Cr, an EBITDA margin of 9–10%, and PAT of ₹65–75 Cr; the actual print cleared all three by a wide margin (revenue ~32% above the top of range, PAT more than double the top of range, margin nearly 400bps above the guided ceiling). Management's own FY27 guidance from the Q4 FY26 call — 6–8% volume growth and EBITDA per tonne at the higher end of ₹19,000–21,000 — cannot be directly checked here since this filing carries no tonnage or segment breakout (the company reports no separate reportable segments under Ind AS 108), but the margin trajectory is directionally consistent with, or ahead of, that guidance. The filing itself carries no management commentary or press release to quote; no qualitative outlook accompanies these numbers beyond the auditor's and secretarial disclosures.
W1
Whether EBITDA/MT lands within management's guided ₹19,000–21,000/MT band for FY27 — this filing discloses no tonnage/segment data to verify directly
W2
Sustainability of the ~₹430.1 Cr revenue / ₹47.8 Cr PAT from the unreviewed overseas subsidiary once fully audited
W3
Whether the OPM jump to ~14% (from 9.25–9.7% in recent quarters) holds next quarter or partly reverts
Clean typed statement, both statements present, no exceptional items this or comparison quarters. One unreviewed overseas subsidiary contributed ₹430.07 Cr revenue / ₹47.84 Cr PAT to consol figures (per auditor's review report) — ~24%/29% of consol totals, based solely on the other auditor's report. GIDC Ankleshwar land dispute (carrying value ₹72.67 Cr) resolved in company's favour post quarter-end.